Non-interventional, cross-sectional study to describe NOACs management in patients with non-valvular atrial fibrillation (NVAF) in Spain. RE-CONOCE study (RE-CONOCE Study)

Study identification

• EU PAS number:
  EUPAS19987
• Study ID:
  33195
• Official title and acronym:
  Non-interventional, cross-sectional study to describe NOACs management in patients with non-valvular atrial fibrillation (NVAF) in Spain. RE-CONOCE study (RE-CONOCE Study)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  This is an observational, multicentre, cross-sectional study based on newly collected data that will be conducted in cardiology departments, in at least 102 centers in Spain.This study observes the use of new oral anticoagulants (NOACs) in patients with a heart rhythm disorder in Spain.The primary objective of the study is to describe the usage of NOACs in patients with NVAF, in the hospital setting, based on the baseline characteristics at the time of first NOAC initiation.Secondary objectives:- To evaluate the appropriateness of prescribed therapy based on Spanish health authorities’ recommendations (positioning therapeutic report)- To describe NOAC treatment management.- To describe the patient’s knowledge about anticoagulant treatment, independent of NOAC type.Further objectives:- To evaluate the appropriateness of prescribed therapy based on Spanish health authorities’ recommendations (positioning therapeutic report) per NOAC type and by autonomous community.
• Study status:
  Finalised

Research institutions and networks

Institutions

Hospital Clínico Universitario de Santiago de Compostela

Multiple centres: 102 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned:01/06/2017

Actual:01/06/2017

Study start date

Planned:27/11/2017

Actual:11/12/2017

Data analysis start date

Planned:01/04/2019

Date of final study report

Planned:24/01/2020

Actual:09/01/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim España, S.A

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable